Fineline Cube

Follow:
14778 Articles
Eli Lilly's Kisunla Receives NMPA Approval for Early Alzheimer's Disease Treatment
CompanyDrug

Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment

BioNova Pharmaceuticals' BN104 Receives Breakthrough Therapy Designation in China
CompanyDrug

BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China

Sinovent Inc. Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA
CompanyDrug

Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
CompanyDeals

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform

GSK's Blenrep and Star Pharma's Topiramate Solution Target Priority Review in China
CompanyDrug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Sciwind Biosciences' Ecnoglutide Accepted for Review by NMPA for Weight Management
CompanyDrug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
CompanyDeals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Everest Medicines' Velsipity NDA for Ulcerative Colitis Accepted by China's NMPA
CompanyDrug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

AstraZeneca's ALXN2350 Selected for CDE's Rare Disease Drug Development Program
Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

NMPA's CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development
Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Perennial Real Estate Holdings' Tianjin Hospital Earns Medical Practice License
Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks
CompanyDrug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks